Following the publication of full data from a late-stage study of La Jolla Pharmaceutical Company (NASDAQ: LJPC)’s LPJC-501, a proprietary formulation of angiotensin II, SunTrust Robinson Humphrey said it expects approval in 2018
Latest Ratings for LJPC
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2017 | SunTrust Robinson Humphrey | Maintains | Buy | Buy |
| Jun 2016 | SunTrust Robinson Humphrey | Initiates Coverage on | Buy | |
| Feb 2016 | Cowen & Co. | Initiates Coverage on | Outperform |
View More Analyst Ratings for LJPC
View the Latest Analyst Ratings
May 22, 2017 at 08:31PM
from Shanthi Rexaline
No comments:
Post a Comment